Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.
Profitability
This table compares Creative Medical Technology and Monopar Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Creative Medical Technology | N/A | -88.38% | -84.71% |
| Monopar Therapeutics | N/A | -12.84% | -12.57% |
Volatility and Risk
Creative Medical Technology has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Creative Medical Technology | $10,000.00 | 444.00 | -$5.99 million | ($2.14) | -0.56 |
| Monopar Therapeutics | N/A | N/A | -$13.72 million | ($1.90) | -46.15 |
Creative Medical Technology has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations and price targets for Creative Medical Technology and Monopar Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Creative Medical Technology | 1 | 1 | 0 | 0 | 1.50 |
| Monopar Therapeutics | 1 | 0 | 10 | 2 | 3.00 |
Monopar Therapeutics has a consensus target price of $107.91, suggesting a potential upside of 23.07%. Given Monopar Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Monopar Therapeutics is more favorable than Creative Medical Technology.
Institutional & Insider Ownership
1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 1.7% of Creative Medical Technology shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Monopar Therapeutics beats Creative Medical Technology on 9 of the 13 factors compared between the two stocks.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
About Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.
